Immunic, Inc. (NASDAQ:IMUX) Receives $9.50 Average Price Target from Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have been given an average recommendation of “Moderate Buy” by the seven analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $9.50.

IMUX has been the subject of a number of analyst reports. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday, September 25th. LADENBURG THALM/SH SH upgraded Immunic to a “strong-buy” rating in a research report on Thursday, October 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a report on Saturday. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Friday, September 26th. Finally, Chardan Capital started coverage on shares of Immunic in a report on Monday, September 29th. They set a “buy” rating and a $13.00 price target for the company.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IMUX. HB Wealth Management LLC acquired a new position in shares of Immunic during the third quarter worth approximately $81,000. Jane Street Group LLC boosted its position in Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after acquiring an additional 152,726 shares during the period. 683 Capital Management LLC boosted its position in Immunic by 28.6% during the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $981,000 after acquiring an additional 200,000 shares during the period. Aberdeen Group plc acquired a new position in Immunic during the 1st quarter worth $1,155,000. Finally, Focus Partners Wealth boosted its position in Immunic by 19.1% during the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after acquiring an additional 415,104 shares during the period. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Stock Performance

NASDAQ IMUX opened at $0.77 on Friday. Immunic has a one year low of $0.56 and a one year high of $1.45. The company has a 50-day simple moving average of $0.86 and a 200-day simple moving average of $0.89. The firm has a market capitalization of $75.71 million, a PE ratio of -0.82 and a beta of 1.56.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Equities analysts forecast that Immunic will post -0.94 earnings per share for the current year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.